Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: A randomized controlled clinical trial. Issue 4 (15th January 2015)

• Record Type: Journal Article
• Authors: Langley, Joanne M.; Frenette, Louise; Jeanfreau, Robert; Halperin, Scott A.; Kyle, Michael; Chu, Laurence; McNeil, Shelly; Dramé, Mamadou; Moris, Philippe; Fries, Louis; Vaughn, David W.
• Is Part Of: Vaccine. Volume 33:Issue 4(2015)
• Page Start: 559
• Page End: 567
• Publication Date: 2015-01-15
• Subjects: Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2014.11.018
• Languages: English
• ISSNs: 0264-410X

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0135"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">We compared an AS03-adjuvanted H5N1 vaccine at different dose levels to placebo.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">We compared the effect of a vaccine boost 6 or 18 months later with a different strain than the priming strain.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">Boosting 6 or 18 months later results in rapid and durable immune responses.</p> </list-item> </list> </p> </sec> </abstract>